Celgene Corp.
(NASDAQ : CELG)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.45%166.930.7%$1253.55m
LLYEli Lilly & Co. 0.18%311.431.1%$814.08m
BMYBristol-Myers Squibb Co. -0.73%70.771.0%$778.85m
PFEPfizer Inc. -1.10%44.080.9%$769.71m
ABBVAbbVie, Inc. 0.04%143.061.9%$735.85m
MRKMerck & Co., Inc. -0.81%86.800.7%$691.58m
AZNAstraZeneca Plc -3.07%54.581.0%$397.16m
ALNYAlnylam Pharmaceuticals, Inc. -0.95%200.788.2%$207.03m
NVSNovartis AG -1.47%76.010.2%$201.13m
GBTGlobal Blood Therapeutics, Inc. 0.03%67.995.4%$199.71m
GSKGSK Plc -2.13%29.370.3%$192.16m
NVONovo Nordisk A/S -0.40%97.920.1%$170.11m
HZNPHorizon Therapeutics Plc 0.54%62.975.4%$156.21m
SGENSeagen Inc. -0.96%139.205.7%$152.48m
SRPTSarepta Therapeutics, Inc. -2.42%108.1912.4%$128.76m

Company Profile

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.